Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives196
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis186
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines179
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review168
Systemic therapy for older patients with early breast cancer125
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in123
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group110
Editorial Board108
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis103
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer91
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas87
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer85
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)78
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer77
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials76
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty72
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches71
If it’s a target, it’s a pan-cancer target: Tissue is not the issue66
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis65
Editorial Board61
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features60
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.59
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?58
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis57
Emerging antibody-based therapies for the treatment of acute myeloid leukemia56
Optimizing care in early phase cancer trials: The role of palliative care53
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies53
Uncertainties and controversies in axillary management of patients with breast cancer53
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck52
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC51
Roadmap to cure multiple myeloma50
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials50
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes50
Editorial Board49
Editorial Board49
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?45
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment45
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges45
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations44
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer44
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review43
Editorial Board41
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis41
The immunogram of inflammatory breast cancer41
Overview of BH3 mimetics in ovarian cancer41
Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination41
0.10728788375854